🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to assess the efficacy, safety, and tolerabili...
Status
Completed
Location
Novartis Investigative Site
Start Date
2011-07
Trial ID
NCT01399125
The purpose of this study is to determine the safety and effects of rivasti...
Status
Completed
Location
Michael E. DeBakey Veterans Affairs Medical Center
Start Date
2009-01
Trial ID
NCT01030692
Treatments Being Tested
Current therapeutic approaches for the treatment of neurodegenerative disea...
Status
Completed
Location
Loghman Hospital
Start Date
2011-01
Trial ID
NCT01696123
Treatments Being Tested
To study the effects of treatment with rivastigmine on craving produced by ...
Status
Completed
Location
Michael E. DeBakey VA Medical Center
Start Date
2009-07
Trial ID
NCT01073319
Treatments Being Tested
This phase IIIb study is intended to implement a consistent treatment way f...
Status
Completed
Location
Novartis Investigative Site
Start Date
2012-08
Trial ID
NCT01585272
Treatments Being Tested
This is a bioequivalence study of Rivastigmine 1.5 mg capsules and Exelon A...
Status
Completed
Location
Multiple Locations
Start Date
2004-01
Trial ID
NCT01146067
Treatments Being Tested
This study is being conducted to determine the safety, tolerability, and ph...
Status
Completed
Location
Pacific Research Network, Inc.
Start Date
2008-10
Trial ID
NCT00766363
Rivastigmine is a carbamate, approved by the FDA for the treatment of mild ...
Status
Completed
Location
Tasmc Clinical Research Center
Start Date
2009-01
Trial ID
NCT00624663
Treatments Being Tested
The goal of this research study is to evaluate, in the open-label extension...
Status
Completed
Location
Multiple Locations
Start Date
2002-02
Trial ID
NCT00130338
Treatments Being Tested
This study used two doses of rivastigmine transdermal patch (5 cm\^2, 10 cm...
Status
Completed
Location
Novartis Investigative Site
Start Date
2007-09
Trial ID
NCT00549601